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Optimization of glycemic control is associated with a lower rate of
target lesion revascularizatiion in treated diabetic patients after drug
eluting stent implantation
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Patients with diabetes mellitus (DM) have increased rates of target lesion
revascularization (TLR) and worse clinical outcome after percutaneous coro-
nary intervention (PCI).
The use of drug eluting stents (DES) appears to largely neutralize the exag-
geration in stent neointimal proliferation. Implantation of DES reduces the rate
of TLR so dramatically that the importance of glycemic control during the
follow up appears unclear.
We sought to determine the influence of glycemic control and its dynamic
changes assessed by preprocedural glycosylated haemoglobin (HbA1c) and at
2-year follow up on rate of TLR in diabetic patients undergoing elective PCI
using DES.
Our monocentric study concerned 184 consecutive diabetic patients under-
going de novo lesions PCI using DES. Preprocedural glycemic control is
assessed by HbA1c1 value and at 2-year follow up by HbA1c2 value. Optimal
glycemic control is defined by HbA1c ≤ 7% and suboptimal glycemic control
by HbA1c> 7%.
The mean age of patients was 65±10 years, 59% were male and 44% are
insulin inquiring patients. Initial angina status was represented by acute coronary
syndrome in 56%, stable angina in 25% and silent ischemia in 19% of cases.
HbA1c1 value was available in 170 patients: 59 patients with HbA1c1 ≤7%
and 111 patients with HbA1c1>7% with a mean HBA1c1 value: 7.9% ± 1.6.
HbA1c2 value was available in 153 patients: 62 patients HbA1c2 ≤7% and 91
patients with HbA1c2 ≥7% with a mean HbA1c2 value 7.6% ± 1.4.
The results showed that only HbA1c2 ≤7% was associated with a signifi-
cantly decreased of TLR (1,7 vs 20,8, p=0,004). In multivariate analysis,
optimal glycemic treatment at long time (HbA1c 2 ≤ 7%) appeared as an inde-
pendent predictive factor of TLR free survival (p<0.001)
In conclusion, whatever the baseline glycemic control, aggressive treatment
of diabetes to achieve A1c levels ≤7% may be beneficial in reducing the rate
of TLR after DES implantation.
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Interest of systematic screening of metabolic syndrome and high car-
diovascular risk in French general healthy population
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Background: Cardiovascular disease is a leading cause of death in France;
knowledge of the importance of risk factors is an important issue.
Methods: Between May 2006 and December 2008, in coordination with
the regional health insurance fund of the Hauts-de-Seine area (CPAM 92), we
performed a systematic screening of cardiovascular risk factors and metabolic
syndrome in a population of men from 45 to 60 years old and women between
55 and 70 years old without any cardiovascular medical history.
Results: 50 000 questionnaires have been sent to residents of nine cities in
Hauts-de-seine area. Answering selection questionnaires rate is about 22%
(10764 persons). 8038 participants were enrolled in our study. 4 081 men (54
years old middle-age) and 4 227 women (62 years old middle-age) have been
included. Among this population, 2000 (20%) persons have a medical history
of hypertension (not well balanced for 51% of them), 1716 have an unknown
hypertension. 20% of participants has a known dyslipidemia (not well bal-
anced: 16%) and 1679 an unknown dyslipidemia (22%). 685 (8,5%) persons
have a medical history of diabetes (not well balanced for 52% of them) and
218 an unknown one. Smokers represents 21% oh this population, more fre-
quently men (28%) than women (13%). Abdominal obesity prevalence is very
high representing in our study 3 100 persons (38%) and affects women (51%)
more often than men (24%). Metabolic syndrome concerns 15% of the patients
(17% of men, 13% of women). Sleepiness on the Epworth sleepiness scale
represents 9%. After global cardiovascular risk assessment, 732 (9%) persons
were classified at high risk of cardiovascular events, 2600 (33%) persons at
moderate risk and 4700 (58%) at lower risk.
Conclusion: According to the important prevalence of patients with a high
risk of cardiovascular events, our study demonstrates the interest of a system-
atic primary screening in a French healthy population.
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Background: After an ischemic stroke, the risk of cardiovascular (CV)
event is high. The effect of optimal control of risk factors on this high morbi-
mortality has not been established in these patients.
Aim: To evaluate the effect of optimized secondary prevention including
dietetic and therapeutic education, on CV risk factor control and CV events
occurrence.
Patients and method:95 selected consecutive patients at high CV risk pro-
file (>3 CVRF) benefited from a 2 days hospitalization 3 months after a stroke
focused on evaluating risk factors and atherosclerosis lesions, and on opti-
mizing treatment and education.
Results: In this high risk population (mean age 60.4±8), we found respec-
tively 24% and 23% of the patients with previously unknown peripheral vas-
cular disease or coronaropathy, and 31% with left ventricular hypertrophy. At
follow-up (median 684 days), 81% of the patients still received a combination
of antiagregant + blood pressure drugs + statin. In term of secondary preven-
tion goals, 73% of the patients had a normal blood pressure, 72% had a LDL
<1g/l, 84% of the diabetics had HbA1c< 7%. 53% of the subjects practiced
recommended physical activity. 24% still smoked.
Conclusion: A global atherosclerosis management and educational pro-
gram of high-risk patients following stroke is beneficial for the long-term con-
trol of cardiovascular risk factors and the sustainability of drug treatments. 
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Metabolic syndrome and coronary heart disease
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ghi, Sonia Hamdi, Mohamed Amine Majdoub, Faouzi Maatouk
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The value of metabolic syndrome (Mets) in the identification of high car-
diovascular risk subjects remains questionable.
We sought to examine the association among Mets and the occurrence of a
coronary heart disease (CHD).
Methods: Between 2006 and 2008, 540 patients were screened for the
Mets according to the NCEP-ATP III definition. The mean age was 61 ± 12.3
 Study REACH France population
Cardiovascular deaths 0 1,7%
Major CV events 7,6% 10,3%
Minor CV events 10,0% 15,3%
